Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study

Eficacia de rituximab comparado con ciclofosfamida en pacientes con manifestaciones graves de lupus eritematoso generalizado. Estudio aleatorizado y multicéntrico

Lilia Andrade-Ortegaa,

Corresponding author

liliaandrade@prodigy.net.mx

Corresponding author.

, Fedra Irazoque-Palazuelosa, Ricardo López-Villanuevab, Yaneth Barragán-Navarroa, Fernando Bourget-Pietrasantac, Maria de los Ángeles Díaz-Ceballosd, Roberto Hernández-Paze, Adelfia Urenda-Quezadaf, Rodolfo Rivas-Ruizg

a Servicio de Reumatología, Centro Médico Nacional 20 Noviembre ISSSTE, Mexico City, Mexico

b Hospital Regional del ISSSTE, Mérida, Yucatán, Mexico

c Hospital Vasco de Quiroga, ISSSTE, Morelia, Michoacán, Mexico

d Hospital General Dr. Darío Fernández Fierro, ISSSTE, Mexico City, Mexico

e Hospital Regional del ISSSTE, León, Guanajuato, Mexico

f Hospital Regional del ISSSTE, Chihuahua, Chihuahua, Mexico

g Hospital Infantil de México Federico Gómez, Mexico City, Mexico

Read

12131

Times
was read the article

5816

Total PDF

6315

Total HTML

Share statistics

Article information

ISSN: 21735743
Original language: English

DOI:10.1016/S2173-5743(10)70058-7

The statistics are updated each day

Year/Month	Html	Pdf	Total
2026 1	245	306	551
2025 12	277	335	612
2025 11	133	230	363
2025 10	10	227	237
2025 9	0	240	240
2025 8	0	159	159
2025 7	0	131	131
2025 6	8	53	61
2025 5	195	95	290
2025 4	149	46	195
2025 3	117	48	165
2025 2	113	46	159
2025 1	122	52	174
2024 12	85	35	120
2024 11	85	77	162
2024 10	82	44	126
2024 9	117	22	139
2024 8	98	36	134
2024 7	125	39	164
2024 6	78	33	111
2024 5	86	33	119
2024 4	79	26	105
2024 3	73	31	104
2024 2	64	25	89
2024 1	62	33	95
2023 12	74	49	123
2023 11	72	59	131
2023 10	87	37	124
2023 9	61	39	100
2023 8	51	13	64
2023 7	69	33	102
2023 6	67	37	104
2023 5	49	18	67
2023 4	46	17	63
2023 3	84	37	121
2023 2	65	25	90
2023 1	93	32	125
2022 12	58	41	99
2022 11	55	36	91
2022 10	40	40	80
2022 9	46	43	89
2022 8	53	50	103
2022 7	43	49	92
2022 6	41	44	85
2022 5	43	57	100
2022 4	52	55	107
2022 3	46	42	88
2022 2	33	37	70
2022 1	61	52	113
2021 12	32	43	75
2021 11	28	44	72
2021 10	50	56	106
2021 9	36	42	78
2021 8	40	49	89
2021 7	30	35	65
2021 6	43	52	95
2021 5	58	32	90
2021 4	116	82	198
2021 3	79	57	136
2021 2	53	37	90
2021 1	42	29	71
2020 12	30	28	58
2020 11	18	23	41
2020 10	16	12	28
2020 9	20	31	51
2020 8	16	23	39
2020 7	26	23	49
2020 6	30	19	49
2020 5	54	33	87
2020 4	55	15	70
2020 3	24	14	38
2020 2	1	0	1
2018 5	7	4	11
2018 4	16	21	37
2018 3	19	20	39
2018 2	8	9	17
2018 1	13	9	22
2017 12	15	16	31
2017 11	18	12	30
2017 10	18	7	25
2017 9	7	9	16
2017 8	15	14	29
2017 7	18	15	33
2017 6	32	22	54
2017 5	26	21	47
2017 4	26	13	39
2017 3	16	24	40
2017 2	11	11	22
2017 1	14	7	21
2016 12	56	23	79
2016 11	27	3	30
2016 10	70	9	79
2016 9	53	17	70
2016 8	49	13	62
2016 7	27	11	38
2016 4	3	0	3
2016 2	2	0	2
2016 1	3	20	23
2015 12	7	0	7
2015 11	0	12	12
2015 10	0	11	11
2015 8	1	0	1
2015 7	22	4	26
2015 6	34	94	128
2015 5	38	54	92
2015 4	32	39	71
2015 3	28	46	74
2015 2	38	28	66
2015 1	26	32	58
2014 12	28	28	56
2014 11	16	44	60
2014 10	23	45	68
2014 9	27	39	66
2014 8	31	31	62
2014 7	32	32	64
2014 6	49	34	83
2014 5	39	24	63
2014 4	27	23	50
2014 3	41	37	78
2014 2	31	25	56
2014 1	30	26	56
2013 12	27	31	58
2013 11	20	31	51
2013 10	32	36	68
2013 9	39	57	96
2013 8	30	63	93
2013 7	23	56	79
2013 6	36	47	83
2013 5	25	53	78
2013 4	33	46	79
2013 3	29	65	94
2013 2	19	34	53
2013 1	23	43	66
2012 12	21	30	51
2012 11	12	22	34
2012 10	12	35	47
2012 9	5	6	11
2012 5	1	0	1
2012 4	5	0	5
2012 3	6	0	6
2012 2	4	0	4
2012 1	3	0	3
2011 12	5	0	5
2011 11	2	0	2
2011 10	1	0	1
2011 9	1	0	1
2011 7	3	0	3
2011 6	2	0	2
2011 5	2	0	2
2011 4	3	0	3
2011 3	5	0	5
2011 2	1	0	1
2011 1	7	0	7
2010 12	15	0	15
2010 11	5	0	5

Show all

Statistics

Subscribe to our newsletter